Abviax's Obefazimod shows promising phase 2b results in ulcerative colitis, with superior safety and efficacy compared to existing treatments, supporting a buy rating. The drug's novel mechanism ...
TAS-205, targeting hematopoietic prostaglandin D synthase, showed no significant efficacy in improving time to rise in DMD patients over 52 weeks. The REACH-DMD trial was a placebo-controlled, ...
ITM-11 significantly improved progression-free survival over everolimus in GEP-NETs patients, marking a first for targeted radiopharmaceutical therapy in a phase 3 trial. The COMPETE trial included ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback